-
Tytuł:
-
Experimental challenges to modeling prostate cancer heterogeneity.
-
Autorzy:
-
Flores-Téllez TDNJ; Prostate Oncobiology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, UK.
Baena E; Prostate Oncobiology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, UK; Belfast-Manchester Movember Centre of Excellence, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, SK10 4TG, UK. Electronic address: .
-
Źródło:
-
Cancer letters [Cancer Lett] 2022 Jan 01; Vol. 524, pp. 194-205. Date of Electronic Publication: 2021 Oct 21.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Limerick : Elsevier Science Ireland
Original Publication: Amsterdam, Elsevier/North-Holland.
-
MeSH Terms:
-
Genetic Heterogeneity*
Neoplasm Recurrence, Local/*genetics
Prostatic Neoplasms/*genetics
Drug Resistance, Neoplasm/genetics ; Humans ; Male ; Mutation ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/therapy
-
Contributed Indexing:
-
Keywords: Cellular and molecular heterogeneity; Extrinsic factors; Intra-tumor heterogeneity; Prostate tumors
-
Entry Date(s):
-
Date Created: 20211024 Date Completed: 20220107 Latest Revision: 20220107
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.canlet.2021.10.012
-
PMID:
-
34688843
-
Tumor heterogeneity plays a key role in prostate cancer prognosis, therapy selection, relapse, and acquisition of treatment resistance. Prostate cancer presents a heterogeneous diversity at inter- and intra-tumor and inter-patient levels which are influenced by multiple intrinsic and/or extrinsic factors. Recent studies have started to characterize the complexity of prostate tumors and these different tiers of heterogeneity. In this review, we discuss the most common factors that contribute to tumoral diversity. Moreover, we focus on the description of the in vitro and in vivo approaches, as well as high-throughput technologies, that help to model intra-tumoral diversity. Further understanding tumor heterogeneities and the challenges they present will guide enhanced patient risk stratification, aid the design of more precise therapies, and ultimately help beat this chameleon-like disease.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
